Ii-Key-nCOV peptide vaccine / Generex, EpiVax - LARVOL DELTA

"Intravacc and EpiVax Collaborate to Develop an Emerging Vaccine for COVID-19 @Intravacc @EpiVax https://t.co/gj4axz9YJk" (@Pharmashot)

Infectious Disease • Novel Coronavirus Disease

Generex Biotechnology Corporation (OTCMKTS:GNBT) plans to use computational tools of EpiVax to develop peptide vaccines against nCOV-2019 coronavirus (Facts About CBD) - “Generex Biotechnology Corporation…entered a pact to utilize the computational tools of EpiVax to develop a Peptide vaccine against nCOV-2019 coronavirus….Generex would use its patented NGIO (NuGenerex Immuno-Oncology) Ii-Key technology together with the computational tools of EpiVax to produce peptide vaccines.”

Licensing / partnership

Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding – WPRI News Channel 12 interview (EpiVax Press Release) - “As the country races to stem the spread of the coronavirus, a Providence-based company is working diligently to create two vaccines against the potentially deadly disease….A vaccine could be ready in five to six months…more than $300 million needed to ensure the vaccine is safe and effective.”

Clinical

Generex Biotechnology provides guidance on the safety of Ii-key peptide vaccines for the development of effective solutions to the SARS-CoV-2 coronavirus pandemic (GlobeNewswire, Generex Biotechnology Corporation) - "Generex Biotechnology Corporation...today provided guidance on their work to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the company’s proprietary and patented Ii-Key immune system activation technology. This guidance is designed to assist third party groups and government agencies in their evaluation of potential vaccines against this pandemic SARS-CoV-2 virus. The patented NuGenerex Immuno-Oncology (Formerly Antigen Express) Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation."

Clinical